Persistent, New Mucus Plugs Associated With Faster Decline in FEV1 in COPD
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 21, 2025 -- For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a faster decrease in forced expiratory volume in one second (FEV1), especially in those who continue or resume smoking, according to a research letter published online in the May 15/22 issue of the New England Journal of Medicine.
Sofia K. Mettler, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues assessed participants in the Genetic Epidemiology of COPD study who had at least 10 pack-years of smoking history to examine the association between change in mucus plugs and decrease in FEV1. Mucus plugs were surveyed with computed tomography at baseline and five-year follow-up. Participants were classified according to change in mucus plugs: persistently negative, resolved, newly formed, and persistently positive.
Five-year follow-up data were available for 2,118 participants. At follow-up, the status changes in mucus plugs were persistently negative, resolved, newly formed, and persistently positive in 44.1, 16.1, 19.7, and 20.1 percent, respectively. The mean decrease in FEV1 was 37.2 mL per year in the persistently negative group compared with 39.3, 54.9, and 60.4 mL per year for the resolved, newly formed, and persistently positive groups, respectively. Compared with the persistently negative group, the difference in FEV1 decrease was meaningful in the persistently positive and newly formed groups and not substantial in the resolved group. The steepest decrease in FEV1 was seen among participants in the persistently positive group who resumed smoking, while the least decrease was seen in the resolved group who quit smoking.
"Persistent and newly formed mucus plugs were associated with a faster decrease in FEV1, a change that was more pronounced in participants who resumed or continued smoking," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 -- Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study...
USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk
WEDNESDAY, July 23, 2025 -- Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.